Conference Coverage
about 24 hours ago
AAO 2025: Imagine what can happen during this collective experienceLatest News
Shorts






Podcasts

Eichenbaum Acorns: A leadership conversation with Rishi P. Singh, MD, FASRS, on advancing CME
Behind the scenes of building impactful educational platforms in retina care

The Retina TL;DR: Rethinking retinal detachment repair with Tony Stefater, MD, PhD; and Tommy Stryjewski, MD
In the debut episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Tony Stefater, MD, PhD; and Tommy Stryjewski, MD, about PYK-2101, a biodegradable retinal sealant designed to replace gas and oil tamponades.

PHOTON Trial Outcomes: Impact on DME Patient Care in Clinical Practice
John Kitchens, MD, and Diana Do, MD, delve into the PHOTON trial results and their significance for treating patients with diabetic macular edema in clinical settings.

PULSAR Study Findings: Implications for Treating nAMD in Clinical Practice
Join John Kitchens, MD, and David Brown, MD, as they explore the PULSAR study results and their impact on managing neovascular age-related macular degeneration in your practice.

Integrating AI to manage DR in a primary care setting
Ehsan Rahimy, MD, speaks on the highlights of a study he presented at this year's virtual AAO 2020 meeting that aimed to integrate an artificial intelligence screening system for managing diabetic retinopathy referrals in a primary care setting — with limited specialty support.

What to expect from virtual AAO 2020
American Academy of Ophthalmology (AAO) President Anne L. Coleman, MD, PhD, offers a preview of what attendees can look forward to from the academy's 2020 virtual annual meeting — kicking off Nov. 13-15.

Spotlighting telemedicine in the year of a pandemic
In this EyePod episode, Ranya Habash, MD, of Bascom Palmer Eye Institute, University of Miami, speaks on the expansion of telemedicine in ophthalmology amid the pandemic and why the future of telemedicine requires a new way of thinking.

Putting in practice retina innovations amid a pandemic
S.K. Steven Houston III, MD, shares how his practice has put to use recent retina innovations and adapted to accommodate the ever-changing operating room spacing and set-up in the current COVID-19 environment.

ASRS 2020: Evaluating 3-year-recurrence rate in non-infectious posterior segment uveitis post-FAi
Dilraj Grewal, MD, associate professor of ophthalmology at Duke Eye Center/ director of grading at the Duke Reading Center, speaks on his presentation "Evaluating the True 3-Year Recurrence Rate in Non-infectious Posterior Segment Uveitis Following an Injectable Fluocinolone Acetonide Insert," during the virtual 2020 ASRS meeting.
Modern Retina Digital Edition


Continuing Medical Education
All News

The Eye Care Network spoke with Sebastian Wolf, MD, PhD, and Sophie Bonnin, MD, PhD, who presented new findings from the OCS-05 phase 2 ACUITY trial.

Behind the scenes of building impactful educational platforms in retina care

The trial results show promising for the evaluated gene therapy for the treatments of LCA, showing significant vision improvements in pediatric patients.

The characteristics of these inherited retinal diseases make it difficult to define objective, clinically meaningful outcomes that are sensitive enough to measure change over the course of a trial.


Broadwood Partners, who is against the merger, holds approximately 27.5% of the outstanding common stock of STAAR, making them the largest outside stockholder of STAAR.

Christine Kay, MD, presents new findings on MCO-010, a novel optogenetic therapy improving vision in retinitis pigmentosa patients at the Retina Society meeting.

Hear highlights from the Vit-Buckle Society and its presence at EURETINA 2025.

Catch up on this week's highlights in retina.

ISTH0036 demonstrates potential to prevent fibrosis, reduce retinal fluid, and improve vision in AMD and diabetic macular edema patients.

The newly approved technology delivers low-dose microcurrents through closed eyelids to stimulate retinal cells.

EURETINA's 25th anniversary meeting attracts 11,000 participants, showcasing cutting-edge research and fostering global networking among retina specialists.

The submission was based on the safety and efficacy data from the phase 3 (RHODOS) and phase 4 (LEROS) studies.

The window shop provision in the Alcon merger agreement enabled STAAR to accept a competing acquisition proposal and terminate the Alcon merger.

Luxa Biotechnology reveals promising phase 1/2a trial results for RPESC-RPE therapy, showing safety and potential vision restoration in patients with dry AMD.

Conavi Medical advances intravascular imaging with its Novasight Hybrid system, enhancing coronary disease diagnosis and treatment through new technology.

Character Biosciences enhances its leadership team and secures $93 million in Series B funding to advance treatments for degenerative eye diseases.

Daniela Bacherini, MD, PhD, FEBO, said modern imaging modalities open up new possibilities in the peripheral retinal space.

Alteogen received a positive CHMP opinion for EYLUXVI in July 2025.

Justis Ehlers discusses promising results from the HELIOS trial, revealing a novel treatment for diabetic retinopathy that may reduce treatment frequency.

Kalaris Therapeutics initiates a phase 1b/2 study for TH103, targeting neovascular age-related macular degeneration and advancing retinal disease treatment.

The country has a goal of ensuring that more than 95% of patients with diabetes receive timely retinal examinations.

Catch up on this week's highlights in retina.

The company’s lead clinical-stage program, OLN324, is a higher potency, higher molar dose VEGF/Ang2 bispecific antibody currently in phase 1b clinical development for patients with either wAMD or DME.

Kodiak Sciences reveals promising APEX study results for KSI-101, showing significant vision improvement in macular edema patients.

The lesion area growth was reduced by more than 50% in the first human clinical trial of K8.

In addition to the proxy statement, STAAR has reached out to all stockholders to ask for their vote to adopt the merger agreement.

New research reveals significant inner retinal impairment in multiple sclerosis patients without optic neuritis, highlighting the need for further studies on macular health.

Belite Bio completes its phase 3 trial for tinlarebant, a potential first treatment for Stargardt disease, with results expected in late 2025.

Kwangdong, a top 5 pharmaceutical and healthcare company in Korea, is actively involved in research and development innovation, including “transformational late-stage, high-impact technologies.”

Optain Health secures $26 million in Series A funding to enhance AI-driven retinal disease detection and expand its technology.

At the EURETINA congress, Prof Pollreisz shared his contemporary approach to multimodal imaging in patients with diabetes.